CD2AP downregulation in brain endothelial cells - memory function

Validation Score: 0.900 Price: $0.50 Alzheimer's disease mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting CD2AP in mice. Primary outcome: memory function impairment

Description

Genetic downregulation of CD2AP specifically in brain vascular endothelial cells to assess the impact on memory function in mice. This experiment examined whether loss of endothelial CD2AP causes cognitive impairments, with particular focus on sex-dependent effects. Male mice showed impaired memory function when brain endothelial CD2AP was reduced.

TARGET GENE

CD2AP

MODEL SYSTEM

mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

cerebrovascular function

SOURCE

extracted_from_pmid_39892386

PRIMARY OUTCOME

memory function impairment

Scoring Dimensions

📖 Wiki Pages

CD2AP Proteinprotein CD2AP Synaptic Dysfunction Alzheimer's Disease Caumechanism CD2AP Gene — CD2-Associated Proteingene Brain Endothelial Cellscell Agitation in Alzheimer's Diseasedisease Alzheimer's Diseasedisease Alzheimer's Diseasedisease Alzheimer's Disease Genetic Variantsdisease Alzheimer's Disease vs Parkinson's Disease Comparidisease APP Mutations in Alzheimer's Diseasedisease DLB, Parkinson's Disease, and Alzheimer's Disease:disease Brain Endothelial Cellscell Investment Landscape: Alzheimer's Diseasedisease Preclinical Alzheimer's Diseasedisease Prodromal Alzheimer's Diseasedisease

Protocol

Establish mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure memory function impairment together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting CD2AP shifts memory function impairment in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (memory function impairment) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

HSP90-Tau Disaggregation Complex Enhancement0.575

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.